+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C



A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C



Clinical and Molecular Hepatology 18(3): 272-278



When combined with pegylated interferon alpha-2b (Peg-IFN α-2b) for the treatment of genotype 1 chronic hepatitis C (CHC) in Korea, the current guideline for the initial ribavirin (RBV) dose is based on body weight. However, since the mean body weight is lower for Korean patients than for patients in Western countries, current guidelines might result in Korean patients being overdosed with RBV. We retrospectively reviewed the medical records of patients with genotype 1 CHC who were treated with Peg-IFN α-2b and RBV combination therapy. We divided the patients into groups A (≥15 mg/kg/day, n=23) and B (<15 mg/kg/day, n=26), given that the standard dose is 15 mg/kg/day. The clinical course in terms of the virologic response, adverse events, and dose modification rate was compared between the two groups after therapy completion. The early response rates (92.0% vs. 83.3%, P=0.634) and sustained virologic response rates (82.6% vs. 73.1%, P=0.506) did not differ significantly between the two groups. During the treatment period, the RBV dose reduction rate was significantly higher in group A than in group B (60.9% vs. 23.1%, P=0.01). RBV dose reduction is performed frequently when patients are treated according to the current Korean guidelines. Given that lowering the RBV dose did not appear to decrease the virologic response during therapy, reducing RBV doses below the current Korean guideline may be effective for treatment, especially in low-weight patients.

(PDF emailed within 1 workday: $29.90)

Accession: 051236456

Download citation: RISBibTeXText

PMID: 23091807


Related references

Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin. Journal of Viral Hepatitis 16(8): 578-585, 2009

Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin. Zhonghua Gan Zang Bing Za Zhi 24(3): 175-180, 2017

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatology 46(6): 1732-1740, 2007

Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype. Journal of Gastroenterology and Hepatology 28(3): 443-449, 2013

Re-treatment virologic response in chronic hepatitis C virologic non-responders and responder-relapsers to interferon monotherapy IFN alpha-2b induction followed by combination ribavirin/interferon alpha-2b vs combination ribavirin/interferon alpha-2b. Gastroenterology 120(5 Supplement 1): A 568, 2001

Early response to combination therapy with low-dose pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C in HIV-infected patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 285, 2001

Virologic response in re-treatment of chronic hepatitis C interferon virologic non-responders and responder-relapsers INF induction followed by combination Ribavirin vs combination Ribavirin High dose IFN. Hepatology 32(4 Pt 2): 557A, 2000

Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon- alpha and ribavirin: a prospective randomized controlled trial. 2007

Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled trial. Intervirology 50(6): 439-446, 2008

PEG-interferon alpha2B plus ribavirin for treatment of patients with chronic hepatitis C who have previously failed to achieve a sustained virologic response following interferon alpha or interferon alpha-2B plus ribavirin therapy. Hepatology 34(4 Pt 2): 419A, 2001

PEG-INTERFERON alpha-2B + RIBAVIRIN FOR TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C WHO HAVE PREVIOUSLY FAILED TO ACHIEVE A SUSTAINED VIROLOGIC RESPONSE FOLLOWING INTERFERON ALFA OR INTERFERON A-2B + RIBAVIRIN THERAPY. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No T1292, 2003

Low dose erythropoietin-beta improves anemia and maintains ribavirin dose in chronic hepatitis C patients receiving combination therapy with ribavirin plus pegylated interferon Alfa-2b. Hepatology Research 39(6): 539-545, 2009

Thymosin Alpha-1 in Combination with Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients Who have Failed to Prior Pegylated Interferon and Ribavirin Treatment. Gut and Liver 1(1): 87-89, 2007

Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience. Journal of Gastroenterology and Hepatology 23(2): 203-207, 2007

Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy. Journal of Medical Virology 80(8): 1363-1369, 2008